NCT02929316 is a Phase 2 clinical trial of Vedolizumab in Celiac Disease, sponsored by AGA Clinical Research Associates, LLC.

Who is sponsoring NCT02929316?

NCT02929316 is sponsored by AGA Clinical Research Associates, LLC.

What drugs are being tested in NCT02929316?

Interventions in NCT02929316: Vedolizumab.

What condition does NCT02929316 study?

NCT02929316 studies Celiac Disease.

Is NCT02929316 still recruiting?

NCT02929316 is currently terminated. Last updated 10 October 2018.

Last reviewed 2018-10-10 · How we verify

NCT02929316

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vedolizumab Induction May Prevent Celiac Enteritis

Terminated Phase 2 Last updated 10 October 2018

What this trial tests

Phase 2 trial testing Vedolizumab in Celiac Disease in 1 participant. Terminated before completion.

Timeline

25 June 2018

Primary endpoint
5 October 2018

5 October 2018

Quick facts

Lead sponsor	AGA Clinical Research Associates, LLC
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	1
Start date	25 June 2018
Primary completion	5 October 2018
Estimated completion	5 October 2018
Sites	2 locations across United States

Drugs / interventions tested

Vedolizumab (vedolizumab) — full drug profile →

Conditions studied

Celiac Disease — all drugs for Celiac Disease →

Sponsor

AGA Clinical Research Associates, LLC

Who can join

Adults 18 to 75, any sex, with Celiac Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Celiac disease (CD) is characterized as an autoimmune disorder whereby gluten (a protein found in wheat, barley, rye, malt) induces an immunological response in genetically susceptible individuals. The prevalence of CD has been estimated to affect 0.5-1% of the population worldwide. Long term sequelae are numerous and include risk of lymphoma, malabsorption leading to weight loss, anemia, multiple vitamin deficiencies, osteoporosis/osteopenia, secondary autoimmunity, etc. (1)

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Evolving Therapy for Celiac Disease.
Yoosuf S, Makharia GK. · · 2019 · cited 54× · PMID 31157194 · DOI 10.3389/fped.2019.00193
Celiac disease: mechanisms and emerging therapeutics.
Besser HA, Khosla C. · · 2023 · cited 31× · PMID 37839914 · DOI 10.1016/j.tips.2023.09.006
New Developments in Celiac Disease Treatment.
Machado MV. · · 2023 · cited 21× · PMID 36674460 · DOI 10.3390/ijms24020945
Gliadin Sequestration as a Novel Therapy for Celiac Disease: A Prospective Application for Polyphenols.
Van Buiten CB, Elias RJ. · · 2021 · cited 14× · PMID 33435615 · DOI 10.3390/ijms22020595
Beyond the gluten-free diet: Innovations in celiac disease therapeutics.
Massironi S, Franchina M, Elvevi A, Barisani D. · · 2024 · cited 9× · PMID 39493330 · DOI 10.3748/wjg.v30.i38.4194
Upcoming Treatments in Celiac Disease: From Luminal Enzymes to Oral Immune Tolerance.
Taavela J, Elli L, Bouma G, Tye-Din JA, et al · · 2026 · PMID 42033586 · DOI 10.1002/ueg2.70222

Verify or expand the search:

Other trials of Vedolizumab

Trials testing the same drug.

NCT06646016 — EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis · Phase 2 · withdrawn
NCT06815003 — Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Di · Phase 2 · recruiting
NCT06227910 — A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease · Phase 3 · recruiting
NCT06443502 — A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pou · Phase 3 · recruiting
NCT06570772 — Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio · Phase 3 · terminated

Other recruiting trials for Celiac Disease

Currently open trials in the same condition.

NCT07239336 — Study of DONQ52 in Active Celiac Disease · Phase 2 · recruiting
NCT07585669 — Effects of Omega-3 Fatty Acids on Inflammation and Gut Microbiota in Celiac Disease · NA · recruiting
NCT07063823 — A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease · Phase 1 · recruiting
NCT06982963 — Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease · Phase 2 · recruiting
NCT07177287 — The Effect of a Navigator Nurse- Supported Mobile Application Developed Based on the IMB Model on the Quality of Life of · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02929316 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AGA Clinical Research Associates, LLC
Last refreshed: 10 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02929316.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing